ACOG Share Price Performance
CA$0
0.00 (0.00%)
Price CA$0
Share Pricen/a
Alpha Cognition Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ACOG Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Alpha Cognition Inc. Key Details
About ACOG
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
